eligibility_summary
Adults 18–70 with BCLC B/C HCC, survival >3 mo, Child‑Pugh A–B (no encephalopathy), LVEF ≥50%, ECOG 0–2, adequate labs (counts OK, ALT/AST ≤5×ULN, bilirubin ≤51 mmol/L or <3×ULN), contraception/negative test if childbearing, able for treatment/follow‑up. Exclude: pregnant/HIV+, active infection/recent antibiotics, significant autoimmune disease or systemic steroids, immune cell therapy <28 d, other cancer <5 y, HF ≥II or uncontrolled HTN, transplant, need warfarin/heparin, allergy to cell therapy, per investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Trial: NCT06463522 (Phase 1/2). Intervention: Autologous tumor-infiltrating lymphocytes (TIL) therapy—personalized cellular immunotherapy (adoptive T-cell therapy), single IV infusion at 2.0×10^7 cells/kg. Mechanism: TILs are patient-derived tumor-resident T cells (primarily CD8+ and CD4+) expanded ex vivo and reinfused to boost antitumor immunity. They recognize tumor/neoantigens via TCR–MHC I/II interactions and kill cancer cells through cytotoxic granule release (perforin/granzyme) and cytokine secretion (e.g., IFN-γ, TNF-α), potentially reshaping the immunosuppressive tumor microenvironment. Targets: Hepatocellular carcinoma cells expressing tumor antigens, immune pathways include TCR signaling, antigen presentation, and T-cell effector cytotoxic pathways. Purpose: assess safety/efficacy in HCC (BCLC B/C).